Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company that is dedicated to developing Precision Therapies in the form of locally delivered, extended-release alternatives to existing drugs. The company's lead product candidate, EP-104IAR, has the potential to address therapeutic areas with high unmet medical needs while providing improved patient benefit through targeted, long-lasting activity with fewer side effects. Moreover, Eupraxia is making strides in developing a pipeline of earlier-stage long-acting formulations, including candidates tailored for post-surgical pain (EP-105) and post-surgical site infections (EP-201). These formulations are designed to enhance the efficacy and tolerability of approved drugs. Notably, the company is also working on a formulation of EP-104IAR for canine and equine osteoarthritis. Founded in 2012, Eupraxia Pharmaceuticals Inc. is positioning itself as a promising player in the biotechnology sector, addressing critical unmet medical needs with its precision therapies.